12.01.2013 Views

2010 November - EHC

2010 November - EHC

2010 November - EHC

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Haemophilia Care in Poland<br />

On 7th September <strong>2010</strong> an international conference “Haemophilia Care in Poland – Current State of<br />

Affairs” took place in Warsaw, Poland. The conference was jointly organized by the Polish<br />

Haemophilia Society and the <strong>EHC</strong>, and the Polish Minister of Health Ewa Kopacz was its official<br />

patron. The speakers included Dr Paul Giangrande, haematology consultant from Oxford Radcliffe<br />

Hospital, Brian O’Mahony, Chief Executive of the Irish Haemophilia Society, Dr Joanna Zdziarska, a<br />

haematologist from the University Hospital in Cracow, Poland, and Bogdan Gajewski, President of<br />

the Polish Haemophilia Society. Also representatives of people with haemophilia and some parents<br />

of children with haemophilia had a chance to express their opinions. The debate was efficiently<br />

moderated by journalist Malgorzata Wisniewska.<br />

The speakers underlined that the introduction of prophylactic treatment for children in 2008 was a<br />

very significant step forward in haemophilia care in Poland. However, there remained many<br />

problems to be solved.<br />

The most important were:<br />

� lack of comprehensive haemophilia care, including problems with access to physiotherapy;<br />

� lack of secondary prophylaxis for adults with serious joint changes;<br />

� wrong costing of medical procedures by the National Health Fund, which was the reason<br />

that hospitals often lost money when treating patients with haemophilia;<br />

� no comprehensive treatment for patients with inhibitors;<br />

� necessity of continuing the existing National Programme of Haemophilia Treatment, which<br />

will expire in 2011;<br />

� no access to recombinant factor concentrates.<br />

When referring to the latter point, Dr Giangrande stressed the fact that prices of plasma-derived and<br />

recombinant factor concentrates had become comparable, and in the most recent tender organized<br />

in the United Kingdom plasma-derived factor concentrates (bought only for patients with von<br />

Willebrand disease as otherwise British patients rely on recombinants) were more expensive than<br />

recombinants.<br />

<strong>EHC</strong> Newsletter| NOVEMBER <strong>2010</strong> 10

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!